Table 2 The extraction recovery and matrix effect data of LXT-101 (n = 3).

From: Development and validation of an LC–MS/MS method for quantitative determination of LXT-101 sustained-release suspension, a novel drug in treating prostate cancer, in beagle plasma

Spiked conc. (ng/mL)

Extraction recovery (%)

IS-normalized matrix effect (%)

Mean ± SD

RSD

Mean ± SD

RSD

5.00

86.67 ± 11.55

13.32

108.50 ± 15.14

13.96

50.00

108.06 ± 16.08

14.88

93.30 ± 11.58

12.40

500.00

96.45 ± 2.02

2.09

88.58 ± 2.04

2.30

Back to article page